John Anderson

Prof. Dr. John Anderson

Department of Nutrition, Schools of Public Health and Medicine, University of North Carolina, 2218 Mcgavran-Greenberg Hl, 135 Dauer Drive, Campus Box 7461, Chapel Hill 27599-7461, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1999 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
JAJohn Anderson
John Anderson
MAMary S Anthony
Mary S Anthony
JCJ Mark Cline
J Mark Cline
SWScott A Washburn
Scott A Washburn
SGSanford C Garner
Sanford C Garner
Objective: To review the current literature on the effects of soy isoflavones, one class of phyto-oestrogens, on cardiovascular diseases, osteoporosis, cancer and climacteric symptoms.Design: Many study designs were employed in the reports reviewed here, including prospective human trials, observational human studies, animal experiments andin vitrocell studies that explored the protective or preventive effects of soy isoflavones (genistein, daidzein and glycitein alone or mixed).Setting: Diverse settings were employed, depending on study design.Subjects: Human subjects, mostly menopausal or postmenopausal, were included, as were animal models and specific cell types.Results: The findings were: (i) isoflavones plus soy protein together were needed to obtain the highly significant beneficial results on blood lipids and arterial dimensions; (ii) isoflavone treatments alone at high doses (relative to above) consistently improved bone parameters in rodent ovariectomized models, but not in humans or primates; (iii) isoflavones were not consistent in exerting positive effects regarding the prevention or treatment of cancers of the mammary glands, uterus and colon; and (iv) the effects of isoflavones on climacteric symptoms were not clear-cut.Conclusions: The promise of soy isoflavones reducing chronic disease risk seems to be non-uniform, with the most conclusive benefits occurring in the prevention of cardiovascular diseases, but other organ systems, such as skeletal and reproductive tissues, may also benefit from the consumption of soy and soy-derived products.

1 June 1999 in Nutrition Research Reviews
Verified
Journal Article
Closed access
JAJohn Anderson
John Anderson
MAMary Anthony
Mary Anthony
MMMark Messina
Mark Messina
SGSanford C Garne
Sanford C Garne
Recent investigations on the effects of phyto-oestrogens on various tissues have revealed that these diverse molecules may improve human health, particularly by protecting against certain chronic diseases. After a brief examination of the food sources, structures, and general cellular actions of the major phyto-oestrogens, current research findings on cardiovascular disease, skeletal tissues, and reproductive cancers are reviewed. Phyto-oestrogen concentrations in blood may be maintained at high levels in those consuming soyabean (Glycine max)-based food daily at several meals and exert their effects on target cells through either genomic effects via the classical oestrogen receptors or non-genomic effects mediated by membrane-bound oestrogen receptors or other cellular proteins. The expression of oestrogen receptor (OR) subtypes alpha (a) and beta (beta) varies across tissues, and cells that preferentially express OR-beta, which may include bone cells, are more likely to respond to phyto-oestrogens. Conversely, reproductive tissues contain relatively more OR-a and may, thus, be differently affected by phyto-oestrogens. Soyabean phyto-oestrogens appear to prevent the progression of atherosclerosis through multiple interactions, including lowering of plasma lipids and lipoproteins, increased vasodilatation and, possibly, decreased activation of blood platelets and vascular smooth muscle cells. However, a favourable impact on cardiovascular disease morbidity and mortality by a soyabean-enriched western-type diet remains to be shown, and unresolved questions remain regarding dose and form of the phyto-oestrogens in relation to risks and benefits. The isoflavones of soyabean have been shown consistently to have bone-retentive effects in animal studies by several investigators using rodent models, although intakes must be above a relatively high threshold level for a lengthy period of time, and little or no extra benefit is observed with intakes above this threshold level. The reports of modest or no effects on prevention of bone loss in human and non-human primate studies respectively, may be due to the limited doses tested so far. The relationship between soyabean-food intake and cancer risk has been more extensively investigated than for any other disease, but with less certainty about the benefits of long-term consumption of phyto-oestrogen-containing foods on prevention of cancer. The observations that breast and prostate cancer rates are lower in Asian countries, where soyabean foods are consumed at high levels, and the high isoflavone content of soyabeans have led to examination of the potential protective effects of phyto-oestrogens. Establishing diet-cancer relationships has proved difficult, in part because of the conflicting data from various studies of effects of soyabean-diets on cancer. Epidemiological evidence, though not impressive, does suggest that soyabean intake reduces breast cancer risk. The isoflavone genistein has a potent effect on breast cancer cells in vitro, and early exposure of animals to genistein has been effective in reducing later development of mammary cancer. Thus, continuous consumption of soyabean foods in early life and adulthood may help explain the low breast cancer mortality rates in Asian countries. Although the evidence for a protective effect against prostate cancer may be slightly more supportive, more research is needed before any firm conclusions can be made about the phyto-oestrogen-cancer linkages.

5 July 2002 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XCX.W Chen
X.W Chen
SGS.C Garner
S.C Garner
JAJohn Anderson
John Anderson

1 October 2002 in Journal of the American College of Nutrition
Verified
Journal Article
Closed access
JAJohn Anderson
John Anderson
XCXiaowei Chen
Xiaowei Chen
ABAgna Boass
Agna Boass
MSMichael Symons
Michael Symons
MKMartin Kohlmeier
Martin Kohlmeier
SGSanford C. Garner
Sanford C. Garner
Background: The effects of isoflavone-enriched soy protein on human bone mineral content (mass) and density in healthy, menstruating young adult females have not been examined in a comparative prospective investigation. Peri- and post-menopausal women have been reported to show beneficial effects of isoflavones on bone measurements. Therefore, young women may also be able to improve their accrual of peak bone mineral content (BMC) and bone mineral density (BMD) during the early adult years of bone consolidation with an isoflavone-enriched diet. Objectives: In this controlled, double-blind intervention, we tested the hypothesis that an isoflavone-rich soy protein diet increases BMC and BMD in young adult females over a period of one year in comparison to a control group receiving soy protein that has isoflavones removed. Design: Young healthy women of any ethnic background, 21 to 25 years of age, were divided into two groups, placebo (n = 13) and supplement (n = 15). The soy protein supplement was enriched with isoflavones (∼90 mg of total isoflavones/day), whereas the control protein diet was isoflavone-deficient, even though it contained the same amount of soy protein and other ingredients as the isoflavone-rich diet. Dual-energy x-ray absorptiometric (DXA) measurements of BMC and BMD were made at baseline and at 6 and 12 months. DXA estimates of body composition, including fat mass and lean body mass, were generated from whole-body BMC measurements. BMI was calculated as weight (kg) over height (m) squared. Physical activity was assessed, and three-day dietary records were taken at entry (baseline) and at 6 and 12 months. Results: No changes in BMD after 12 months were found in either the isoflavone-treated (treatment) group or the isoflavone-deficient (control) group. Other variables also remained essentially constant over the 12-month period, including normal menstrual patterns in both the treatment and control groups. Conclusions: The isoflavone-rich soy preparation had no effects on BMC and BMD over a 12-month period in young healthy adult females with normal menses. An isoflavone-rich supplement appears to have little or no effect on bone in young adult women with normal ovarian function, at least over this 12-month study period.

12 July 2013 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JAJohn Anderson
John Anderson

1 June 2000 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
JAJohn Anderson
John Anderson
Skeletal development requires reasonable intakes of all the nutrients required by bone tissue, but energy and protein are critical for attainment of growth commensurate with hereditary determinants. Although clearly important for skeletal development, the amounts of calcium needed for optimizing skeletal mass and size remain difficult to determine. Many children in both developed and developing nations gain near-optimal skeletal mass and size with low calcium intakes, without adverse effects. A currently missing determinant in most considerations of requirements by nutritionists is the lifestyle variable of physical activity.